HIV: Markets for Diagnostics and Therapeutics

Published by	Kalorama Information
Published	October, 2008	Product code	74797
Content info	250 pages
Price	US $ 2995 PDF by E-mail (Single User License) US $ 3900 Hard Copy US $ 6995 PDF by E-mail (Global Site License)

Introduction
Press Release
Related Reports

HIV: Markets for Diagnostics and Therapeutics published by Kalorama Information in October, 2008. This report consists of 250 pages and the price starts from US $ 2995.

Introduction

Abstract

The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology.

In his report HIV Markets for Diagnostics and Therapeutics, anlayst Kenneth Krul, PhD examines these focal points, with an eye to creating a comprehensive look at the market and opportunity for both testing and treatments of HIV. Dr. Krul takes a look at the potential theoretical markets and what will be realistic in the current world healthcare system.

The report contains extensive epidemological statistics for HIV in the following WHO health regiions:

Sub-Saharan Africa
Middle East and North Africa
South and South-East Asia
East Asia
Latin America
Caribbean
Eastern Europe and Central Asia
Western and Central Europe
North America
Oceania

In addition the report contains:

Current Market Sizes for HIV Treatments and Diagnostics in each WHO Health Region (treatment and diagnostic markets)
Profiles of Companies in this Market
Eleven Important Conclusions
Review of Current Treatment Products and Diagnostic Tools.

As with all Kalorama Information reports, this product is the result of primary and secondary research. Interviews with experts, as well as research into company reports, medical literature and government data is included.

CHAPTER ONE: EXECUTIVE SUMMARY

Potential and Realistic Markets
Figure 1-1: gTheoreticalh Distribution of HIV Market
Figure 1-2 Realistic Market for HIV/AIDs Diagnostics
Table 1-1: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008
Table 1-3: Regional HIV/AIDS Statistics: 2001 and 2007
Technology
Key HIV/AIDS Market Issues
Scope and Methodology

CHAPTER TWO: INTRODUCTION AND EPIDEMIOLOGY

HIV/AIDS Complications
HIV/AIDS Epidemiology
Table 2-1: Global Summary of HIV/AIDS Populations: 2007 (Category, Average, Range)
Figure 2-1: Estimated People Living With HIV/AIDS Globally: 1990 - 2007
Figure 2-2: Estimated Number of Adult and Child Deaths Due to AIDS Globally: 1990 - 2007
Figure 2-3: Estimated Incidence of HIV Infection Globally: 1990 - 2007 Sub-Saharan Africa
Table 2-2: Regional HIV/AIDS Statistics (I): 2001 and 2007 (Millions)
Table 2-3: Regional HIV/AIDS Statistics (II): 2001 and 2007
Figure 2-4: Estimated HIV Prevalence Rates (%) in Adults (15 - 49 Years) Globally and in Sub-Saharan Africa: 1990 - 2007
Table 2-4: Adult (Aged 14 - 49 years) HIV Prevalence in Sub-Saharan Countries That Have Recently Conducted Population-Based HIC Studies
Table 2-4 (continued): Adult (Aged 14 - 49 years) HIV Prevalence in Sub- Saharan Countries That Have Recently Conducted Population-Based HIC Studies
Asia
Eastern Europe and Central Asia
The Caribbean
Latin America
North America, Western and Central Europe
Figure 2-5: AIDS Distribution by Race in the United States: 2006
Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
Table 2-5: Prevalence of HIV Infection in the United States Based on Sample Testing: 2006
Figure 2-5: AIDS Distribution by Race in the United States: 2006
Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
Figure 2-7: Risk Factors Associated with AIDS in Women in the United States: 2006
The Middle East and North Africa

CHAPTER THREE: HIV/AIDS SCREENING AND DIAGNOSIS

Level 1: Screening
Level 2: Confirmatory Testing
Level 3: Diagnosis
Table 3-1: HIV Screening and Confirmatory Testing Products Approved for Use in the United States as of July 9, 2008
Table 3-2: Conditions Attributable to or Complicated by HIV
Table 3-3: AIDS Indicator Conditions
Level 4: Monitoring Treatment and Prognosis

CHAPTER FOUR: HIV/AIDS THERAPEUTICS

Drug Therapy
Figure 4-1: Binding of HIV to T-Cells
Table 4-1: HIV Entry/Fusion Inhibitors; FDA-Approved and in Development: 2008
Table 4-2: Nucleoside Reverse Transcription Inhibitors (NRTI); FDA-Approved and in Development: 2008
Table 4-3: Non-Nucleoside Reverse Transcription Inhibitors (NNRTI); FDA-Approved and in Development: 2008
Figure 4-3: HIV Integration
Table 4-4: Integrase Inhibitors; FDA-Approved and in Development: 2008
Figure 4-4: HIV Transcription
Figure 4-5: HIV Translation
Figure 4-6: HIV Assembly and Maturation
Table 4-5: Protease Inhibitors (PI)/Maturation Inhibitors (MI); FDA-Approved and in Development: 2008
Pediatric HIV/AIDS
Table 4-6: Anti-HIV Drugs in Development: 2008
Table 4-7: Anti-HIV Drugs Approved for Pediatric Use
Chemokine Therapeutics and HIV
Genes and HIV/AIDS
HIV/AIDS Vaccines

CHAPTER FIVE: MARKET ANALYSIS

Table 5-1: Estimated Theoretical Potential for HIV/AIDS Diagnostics and Therapeutics: 2008
Figure 5-1 HIV/AIDS Market by Major World Regions
Table 5-2: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008 Technology Key HIV/AIDS Market Issues

CHAPTER SIX: COMPANY SNAPSHOTS

Abbott Laboratories
Abbott Molecular Diagnostics
Bristol-Myers Squibb
Calypte Biomedical Corp.
Celera Diagnostics
Gen-Probe Incorporated
Gilead Sciences
GlaxoSmithKline plc
Luminex Corporation
QIAGEN GmbH
Roche Molecular Systems
Tibotec, Inc. (A Johnson & Johnson Company)
VIRxSYS Corporation

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion
Eighth Conclusion
Ninth Conclusion
Tenth Conclusion
Eleventh Conclusion

CHAPTER EIGHT: GLOSSARY

Press Release

New Maturation Inhibitor Drugs May Provide Solution to HIV Treatment Conundrum

October 15th, 2008

Since AIDS was first recognized in 1981, significant advances have been made in developing an effective arsenal of drugs to manage the disease and extend patients lives. However, HIVs ability to mutate and become resistant to current drugs is a persistent threat, and many patients dont benefit from or cannot tolerate complex combination regimens. According to a new report from Kalorama Information entitled "HIV: Markets for Diagnostics and Therapeutics," research is underway to develop more potent therapies that have fewer toxic effects and are easier to administer, including a new category of anti-HIV drugs called maturation inhibitors.

Maturation inhibitor treatments may provide a viable solution to the HIV treatment conundrum. They are one of several new treatments showing promise and driving the world market, which Kalorama estimates at $20.8 billion in 2008, with a theoretical potential of $253.3 billion.

"Viral maturation is the process that occurs during the last stages of HIV reproduction after the virus has been released from an infected cell," notes Kenneth Krul, PhD, the author of the study. "It involves the processing of viral protein for the infected cell and is required for the virus to become infectious. These new treatments work by inhibiting the viral maturation process so new viruses cannot go on to infect other cells in the body."

One such first-in-its-class maturation inhibitor is Bevirimat, which functions to release noninfectious particles and to terminate viral replication. Bevirimat is currently in Phase II clinical trials. It is being evaluated as an oral, once-daily monotherapy for activity against HIV-1 in patients who are resistant to available treatments or in those who are infected with wild-type HIV-1 strains.

Kalorama Informations report, "HIV: Markets for Diagnostics and Therapeutics," includes a comprehensive look at the market and opportunity for both testing and treatments, examines the potential theoretical markets and what will be realistic in the current world healthcare system. Extensive epidemiological statistics for HIV in ten World Health Organization (WHO) health regions are provided.